Open Access

The relationship between epilepsy and sexual dysfunction: a review of the literature

SpringerPlus20165:2070

https://doi.org/10.1186/s40064-016-3753-5

Received: 18 March 2016

Accepted: 26 November 2016

Published: 2 December 2016

Abstract

Background and objectives

Regardless of the disease states that people suffer from, maintaining sexual function is an important indicator of quality of life. The objective of this review was to figure out the relationship between epilepsy, antiepileptic drugs (AEDs) and sexual dysfunction.

Results

In various epidemiological and clinical studies, epilepsy has been correlated with a reduction in sexual function. This sexual dysfunction is not always detected in epileptic patients until systematic efforts are put in place, as part of the assessment and treatment process. Therefore, precise evaluations of the incidence of treatment related sexual dysfunction in epileptic patients is still lacking.

Conclusions

This literature review concluded that sexual function is influenced by the pathophysiology of epilepsy, as well as through the use of AEDs. To maximize quality of care in patients with epilepsy and those patients with other disease states who receive AEDs, it is important to address the status of the patient’s sexual function as part of the initial routine assessment and with any treatment related follow-up. Minimizing the effects of AED related sexual dysfunction can be achieved by raising awareness among patients, providing education and training for physicians regarding sexual dysfunction and obtaining a baseline sexual history from the patient so are important recommendations. In addition, systematic studies are needed to explore the risk and mechanism of such treatment related side effects on sexual function.

Keywords

Epilepsy Sexual dysfunction Antiepileptic drugs Epidemiology Relationship

Background

Historically discussion around sexual practices and associated dysfunction was taboo. However, in the modern era, awareness of issues associated with sexual dysfunction has been more commonly aired. Western civilization has become more open-minded about discussing sexual dysfunction, and in particular about erectile dysfunction (ED) in men, often associated with chronic disease. With this opening up of society there has been encouragement for people to think about their sexual performance and to seek advice from health consultants (Laumann et al. 1999; Kaufman et al. 2015).

The very first orally available drug for male ED was sildenafil (Viagra) which not only treated the problem but also through marketing campaigns, increased awareness among people. These days ED is considered amongst the general public to be a “medical condition” that can be managed. In terms of etiology both physical (ED in men due to circulatory disorders) and psychological factors (inadequate interpersonal associations, psychiatric illness) are responsible for sexual dysfunction. Another cause of sexual dysfunction is the use of drugs such as anti-hypertensive (Fogari et al. 1998), anti-psychotics (Baldwin and Birtwistle 1997), anti-depressants (Baldwin et al. 1997; Goldstein and Goodnick 1998) and anti-epileptic drugs (AEDs) (Hamed et al. 2015; Kirmani et al. 2014; Lombardi et al. 2015; Meryn 2015; Svalheim et al. 2015; Urso et al. 2014; Kaufman et al. 2015; Sivaraaman and Mintzer 2011; Kaufman and Struck 2011b). The link between sexual dysfunction and drug induced as opposed to disease induced effects is complicated, and the case of epilepsy and AEDs has received less attention than one might expect. Sexual dysfunction may impact on compliance and is reported to be dose dependent with various AEDs (Kaufman and Struck 2011a). For example, case reports of gabapentin-induced sexual dysfunction suggest that the minimum total daily dose required for sexual dysfunction is 900 mg (Dalal and Zhou 2008; GRANT and OH 2002).

The human sexual response and sexual dysfunction

Natural sexual response of a human can be divided into four stages and disturbance can occur in any one these stages;
  1. 1.

    Desire typically this consists of fantasies about, and the desire to have, sexual activity.

     
  2. 2.

    Excitement the individual sense of sexual enjoyment, associated with physiological alterations, including penile tumescence and erection in men, and pelvic vasocongestion, inflamed external genitalia, and lubrication and extension of the vaginal canal in women.

     
  3. 3.

    Orgasm height of sexual enjoyment, by the discharge of sexual tension and rhythmic contraction of perineal muscles as well as reproductive organs.

     
  4. 4.

    Resolution sense of comfort and muscular leisure. Physiologically men are noncompliant to erection and orgasm for a varied time period, while women might be capable to respond to additional stimulation.

     
The label ‘sexual dysfunction’ has been classified in the International Classification of Mental and Behavioral Disorders, 10th edition (ICD-10) (World Health Organization 1992) (for those people who were incapable of enjoying their sexual relationship as they want). The ICD-10 sexual dysfunction categorization is not based on organic pathophysiology or infection. Both ICD-10 and Diagnostic and Statistical Manual of Mental Disorders, fourth edition (DSM-IV) (American Psychiatric Association 2000) utilized the same classificatory proposal (Table 1).
Table 1

Standard classification system for sexual dysfunction

F52.0

Lack or loss of sexual desire

F52.1

Sexual aversion and lack of sexual enjoyment

F52.2

Failure of genital response

F52.3

Orgasmic dysfunction

F52.4

Premature ejaculation

F52.5

Non-organic vaginismus

F52.6

Non-organic dyspareunia

F52.7

Excessive sexual drive

F52.8

Other sexual dysfunction, not caused by organic disorder or disease

F52.9

Unspecified sexual dysfunction, not caused by organic disorder or disease

Men and women can both suffer from sexual dysfunction the difference being women tend to express a lack of sexual enjoyment and/or interest, whilst men face sexual dysfunction related largely to physical response including failure to achieve an erection and/or premature ejaculation (McCabe et al. 2016). There has been dialogue to suggest that the categorical approaches to sexual dysfunction as defined by the ICD-10 and DMS-IV highlight the obscure, diverse and exclusive approaches whereby any person or couple could share their sexual problems (Bancroft 2009). It is evident if any phase of sexual response is changed, other phases may also be affected. Therefore, for diagnosis and subsequent treatment to be successful with sexual dysfunction it is essential to intervene with any relevant presenting complaint, rather than merely focusing on the standard diagnostic criteria.

Epidemiology of sexual dysfunction

The epidemiology of sexual dysfunction has not been broadly discussed in the literature; or at least the literature has not been reviewed and synthesized. Thirty years ago prevalence data for sexual dysfunction were derived according to the DSM-III by Nathan et al., who analyzed twenty two studies about sexual dysfunction in the general population. Methodological issues in this analysis indicated that an extensive estimation might be made (Nathan 1986). The incidence of reduction of sexual desire was found to be 35% in women, 16% in men, premature ejaculation 35% and ED 10–20% in men and in female, orgasmic complication was found to be 5–15%. According to a study conducted in the United States (US), sexual dysfunction was more common in women (43%) than men (31%) (Laumann et al. 1999). In the case of women, low sexual desire (22% prevalence), arousal difficulty (14%) and sexual pain (7%) have been observed. Whilst for men premature ejaculation (21%), low sexual desire (5%) and ED (5%) have been observed. Sexual dysfunction rates can be different depending upon the population being studied and the nature of sexual dysfunction being evaluated. The data represented here demonstrates a high prevalence of sexual dysfunction for both males and females (Christensen et al. 2011; Ernst et al. 1993; Lindau et al. 2007; Hendrickx et al. 2016). Table 2 summarizes the key findings of studies published on sexual dysfunction among the general population.
Table 2

Studies of sexual dysfunction in the general population

Population

Subjects (M/F)

Dysfunctions assessed (%)

References

40-year-old Danish women

0/324

Impaired interest (41.8), orgasmic difficulties (36.7), dissatisfaction (35.4), pain/dyspareunia (1.3)

Garde and Lunde (1980)

35–59-years-old Oxford women

0/521

Impaired interest (17), orgasmic difficulties (16), pain/dyspareunia (8)

Osborn et al. (1988)

29-year-old men, 30-year-old women

197/218

Men dissatisfaction (21), impaired interest (7), premature ejaculation (4)

Ernst et al. (1993)

Women dissatisfaction (21), impaired interest (16), orgasmic difficulties (7), pain/dyspareunia (6)

Iranian women aged 20–60-years-old

0/2626

Orgasmic difficulties (37), low sexual desire (35), lubrication disorders (33.7), dissatisfaction (31.5), arousal disorders (30), pain/dyspareunia (26.7)

Safarinejad (2006)

US adults (57–85-years of age)

1455/1550

Men erectile difficulties (37), lack of interest in sex (28), climaxing too quickly (28), anxiety about performance (27), inability to climax (20)

Lindau et al. (2007)

Women lack of interest in sex (43), lubrication disorders (39), inability to climax (34), finding sex not pleasurable (23), pain (17)

British women aged 18–85-years-old.

0/1489

Low sexual desire (17.3), dissatisfaction (14.6), orgasmic difficulties (13.5), arousal disorders (13.3), lubrication disorders (11.5), pain/dyspareunia (11.5)

Burri and Spector (2011)

Danes aged 16–95-years-old

2120/2295

Men premature ejaculation (7), erectile dysfunction (5), anorgasmia (2), dyspareunia (0.1)

Christensen et al. (2011)

Women lubrication insufficiency (7), anorgasmia (6), dyspareunia (3), vaginismus (0.4)

Swiss men aged 18–25-years-old

3886/0

Erectile dysfunction (29.9), premature ejaculation (11.4)

Mialon et al. (2012)

Flemish men and women 14–80-years-old

651/695

Men erectile dysfunction (7.1), premature ejaculation (6.3), hyperactive sexual desire (3.3)

Hendrickx et al. (2016)

Women lubrication dysfunction (9.6), absent or delayed orgasm (7.4), low responsive sexual desire (6.9), low spontaneous desire (5.3)

The major categories of sexual dysfunction are influenced by various aspects. First, the means of enquiry and type of data reporting mechanism i.e. the occurrence of sexual dysfunction in one prospective study was 14% when relying on spontaneous self-reporting, but 58% when the doctor directly asked the patient about it (Montejo-Gonzalez et al. 1997). Second, the attitudes of people with respect to disclosing and fully discussing their sexual dysfunction issues with their physician is strongly influenced by the culture of a society (Bhavsar and Bhugra 2013).

To provide an example, this is especially the case with Muslim people whereby discussing anything sexually-related, including issues like sexual dysfunction outside of marriage is prohibited. This can make it very difficult for Muslim clients to seek help from health professionals; however, there mechanisms in place where it may be allowed for treatment purposes (Sungur and Bez 2016). Any sexual activity outside of marriage is also banned under Islam, but the religion encourages the enjoyment of sex and sensitivity to the needs of the spouse within heterosexual marriages. Therefore, it is critical for health professionals to be aware of the role of culture in defining sexual dysfunction and how cultural factors can be considered when initiating treatment as well as in therapeutic engagement and alliance between patient and practitioner.

Third, sexual dysfunction can be defined in many terms and is reliant on the belief of what is usual or normal in a sexual relationship (Bhugra and de Silva 2007). Finally, temporal trends can occur with spikes in concern about disorders, as increased awareness of sexual matters and availability of medical treatments increase the numbers who perceive themselves as suffering from sexual dysfunction and come forward to seek treatment (Baldwin 2001).

Sexual dysfunction in epileptic patients

Epilepsy is a significant chronic neurologic disorder characterized by episodes of seizure (of various types), which generally require lifelong management with medication (Atif et al. 2016). Children and adults are both affected by this disease. Approximately 1 in 26 people will develop epilepsy at some point in their lives (England et al. 2012). Sexual dysfunction associated with epilepsy is not yet completely understood (Harden 2008) and epilepsy is a complex disease causing several downstream pathological alterations which may need further exploration and treatment. One manifestation of the disease includes endocrine disorders in men and women which influences the reproductive system. Reproductive endocrine disorders in epileptic women include polycystic ovary syndrome (PCOS) (Bauer and Cooper-Mahkorn 2008; Bilo et al. 1988; Herzog et al. 2003a, b, 1984; Hopkinson et al. 1998; Gorkemli et al. 2008), hypothalamic amenorrhea (Bilo et al. 2001; Herzog et al. 1986b), hyperandrogenemia (HA) (Luef et al. 2002b; Löfgren et al. 2007), galactorrhea, hirsutism, menstrual abnormality and infertility (Bauer 2001; Bauer et al. 2002; Herzog et al. 2003b; Löfgren et al. 2006). Sexual dysfunction impacts between one and two thirds (30–66%) of epileptic men (Blumer and Walker 1967; Hierons and Saunders 1966; Herzog et al. 1986a) and between 14 and 50% of epileptic women (Demerdash et al. 1991; Jensen 1992). Evidence suggests that (Edwards et al. 1999; Baird et al. 2003; Quigg et al. 2002; Morrell et al. 2005) patients with partial epilepsy (PE) are more severely affected by reproductive endocrine and sexual dysfunction than idiopathic generalized epileptic (IGE) patients, predominantly of temporal lobe origin (Table 3).
Table 3

Studies of epilepsy type and sexual and reproductive dysfunction

Dysfunction assessed

Epilepsy type

Sex (n)

Prevalence

Sexual dysfunction assessment

References

Sexual

i. Global anorgasmia

ii. Vaginismus

iii. Dyspareunia

PE

F (99)

i. 17.9%

ii. 27.8%

iii. 38.5%

Questionnaire

Morrell and Guldner (1996)

IGE

F (17)

i. 31.3%

ii. 13.3%

iii. 18.8%

 

i. Sexual arousability

ii. Sexual anxiety

PE

F (99)

i. 72.2%

ii. 15.4%

Questionnaire

Lambert (2001)

IGE

F (17)

i. 84.2%

ii. 7.6%

Erectile dysfunction

GTCS

M (25)

72%

Questionnaire

Nikoobakht et al. (2007)

PE

M (16)

32%

Erectile dysfunction

PE

M (418)

25.8%

Clinical interview

Keller et al. (2012)

IGE

M (166)

29.5%

Reproductive

i. Menstrual disorders

ii. PCO

iii. HA

iv. PCOS

PE

F (90)

i. 44%

ii. 46%

iii. 33%

iv. 44%

Clinical examination, transvaginal ultrasonography

Löfgren et al. (2007)

IGE

F (57)

i. 29%

ii. 28%

iii. 13%

iv. 19%

i. Menstrual disorders

ii. Hirsutism

iii. PCO

IGE

F (52)

i. 23%

ii. 5.8%

iii. 25%

Clinical examination, transvaginal ultrasonography

Luef et al. (2002a)

PE

F (40)

i. 42.5%

ii. 2.5%

iii. 37.5%

PCO

IGE

F (36)

21%

Suprapubic ovary ultrasound

Murialdo et al. (1997)

PE

F (65)

14.5%

i. Hypomenorrhoea

ii. Amenorrhea

iii. Oligomenorrhoea

iv. Polymenorrhoea

IGE

F (21)

Overall results

i. 22%

ii. 16%

iii. 9%

iv. 2%

Clinical examination

Demerdash et al. (1991)

PE

F (106)

PCO polycystic ovaries, HA hyperandrogenism, PCOS polycystic ovary syndrome, IGE idiopathic generalized epilepsy, PE partial epilepsy, F female

The underlying mechanism of reproductive dysfunction has various hypotheses. One of the most accepted hypotheses suggests that the activity of gonadotropin-releasing hormone (GnRH) pulse generator is disturbed due to the temporal lobe regions associated with epilepsy, which might be the origin of paroxysmal release, just before the hypothalamus (Verrotti et al. 2015). Amplification of the pulse frequency of GnRH and as a result the luteinizing hormone (LH) and follicle-stimulating hormone (FSH) ratio is related among PCOS patients (Rauchenzauner et al. 2014). The decrease in GnRH pulse frequency also lowers LH and estrogen (E2) levels, which an attribute is of HA. Moreover, several other aspects, such as, obesity, genetic disposition, laterality of epilepsy, type of AED prescribed, age and severity of seizures, might also be reasons for clinical expression of specific reproductive disorders i.e. HA, PCOS, ovulation, hirsutism (Verrotti et al. 2011).

The relationship between sexual dysfunction and AEDs

Seizure disorders are linked with sexual dysfunction as part of the pathophysiology, whilst all the available AEDs have not yet been definitively proven to have negative impacts on sexual function. As such, evaluation of AED-induced sexual dysfunction is complicated and less than clear (Crenshaw and Goldberg 1996; Gitlin 2003). Comparative analyses of AEDs in patients with epilepsy, inducing sexual dysfunction are hard to find. The enzyme stimulating AEDs (phenytoin, topiramate, phenobarbital, oxcarbazepine and carbamazepine) raise hepatic synthesis of sex hormone binding globulin (SHBG) that lessens the accessibility of testosterone. Additionally, enhanced sex hormone metabolism and contraceptive hormones are not found with the use of AEDs that do not stimulate hepatic enzymes (e.g. lamotrigine, valproate, gabapentin, and vigabatrin) (Herzog et al. 2005; Morrell 2003). A consistent finding in the literature is that sexual dysfunction occurs with greater prevalence in patients taking phenytoin and carbamazepine than in patients taking valproate or lamotrigine (Herzog et al. 2005; Gutierrez et al. 2008). Women treated with valproate for bipolar disorder have also been reported to have severely decreased libido and anorgasmia, while there are case reports of gabapentin-associated anorgasmia in women who suffer from epilepsy (Harden 2005). A review of pregabalin efficacy and tolerability makes no mention of sexual dysfunction as an observed adverse effect (Tassone et al. 2007). Several studies in men and women have indicated that AEDs are related to sexual dysfunction (Table 4).
Table 4

Anti-epileptic drugs associated with sexual dysfunction

Drug and dose (mg)

Dysfunction assessed

Sex (n)

Prevalence

Diagnosis

Sexual dysfunction assessment

References

Sexual dysfunctions

Primidone (250)

Decreased libido or impotence

M (109)

22%

GTCS

Questionnaire

Mattson et al. (1985)

Carbamazepine (580)

Sperm abnormality

M (13)

77%

IGE, PE

Semen analysis and ultrasonography of testicles

Isojärvi et al. (2004)

Oxcarbazepine (1060)

M (17)

59%

Valproate (1080)

M (25)

80%

Topiramate (100–200)

Erectile dysfunction

M (40)

5%

PE

Clinical interview

Holtkamp et al. (2005)

Valproate (400–1250)

i. Erectile dysfunction

ii. Premature ejaculation

iii. Orgasm dysfunction

iv. Diminished sexual desire

M (8)

i. 50%

ii. 50%

iii. 0.0%

iv. 62.5%

GTCS

Sexual function questionnaire

Hamed et al. (2006)

Carbamazepine (400–1000)

M (17)

i. 47.1%

ii. 35.3%

iii. 5.9%

iv. 52.9%

Pregabalin (150–600)

Erectile dysfunction

M (363)

3.0%

PE

Questionnaire

Hitiris et al. (2006)

Lamotrigine (50–200)

Lack of sexual interest

M (75), F (66)

11%

Complex PE, IGE

Changes in sexual functioning questionnaire (CSFQ)

Gil-Nagel et al. (2006)

Phenytoin (100)

Retrograde ejaculation

M (1)

Case report

PE

Clinical examination

Elia et al. (2010)

Zonisamide (200)

Erectile dysfunction

M (1)

Case report

PE

Clinical interview

Maschio et al. (2011)

Gabapentin (900)

Anorgasmia

F (1)

Case report

GTCS

Clinical interview

Perloff et al. (2011)

Leviteracetam (2000–3000)

i. Decreased libido

ii. Erectile dysfunction

iii. Anhedonia

M (2)

Case reports

GTCS, Myoclonic seizures

Clinical interview

Calabrò et al. (2012)

Pregabalin (300)

Anorgasmia

M (4)

Case reports

PE

Clinical interview

Calabrò et al. (2013)

Leviteracetam (500–1000)

Sperm abnormality

M (10)

69.2%

GTCS, complex PE

Computer-aided sperm analysis

Xiaotian et al. (2013)

Valproate (500–1000)

M (15)

18.8%

Lacosamide (400)

i. Loss of libido

ii. Erectile dysfunction

M (1)

Case report

Simple and complex seizures

Clinical examination

Calabro (2016)

GTCS generalized tonic–clonic seizure, PE partial epilepsy, IGE idiopathic generalized epilepsy

Antiepileptic drugs, epilepsy and serum sex hormones

Sex hormones levels contribute to sexual dysfunction as well as other reproductive disorders and these levels can be change as a result of the administration of AEDs (Table 5) (Morrell et al. 2005). The reproductive endocrine system may also be influenced by the pathophysiological effects of epilepsy as a disease in its own right (Scharfman et al. 2008). Endocrinological alterations due to epilepsy can be postulated in spite of the complicated interconnection among the limbic system and the hypothalamic–pituitary axis (HPA). Production toward HPA from the limbic cortex, containing nuclear configuration inside the amygdale, can alter key features in the discharge of sex hormones. Reproductive functions and discharge of sex hormones are affected by the influence of epilepsy in the medial temporal lobe region of the brain (Herzog et al. 1986b). Though the complexity it remains uncertain as to whether hormonal irregularity is because of epilepsy associated HPA dysfunction or whether it is due to the side effects of AEDs (Verrotti et al. 2011). The role of the HPA, the production of LH and FSH, GnRH, prolactin (PRL), and the end products of metabolism and their concentrations i.e. E2, T (testosterone), and DHEAS (dehydroepiandrosterone), are altered in epileptic women (Table 5) (Morrell 2003; Genton et al. 2001).
Table 5

Serum sex hormone and sex hormone-binding globulin (SHBG) concentrations in various studies

AEDs

Sex (n)

SHBG

T

FT

DHEAS

DiT

FAI

E2

A

Comments

References

Carbamazepine, valproate

M (37)

NA

NA

NA

NA

NA

Libido and fertility are low in epileptic patients

Dana-Haeri et al. (1982)

Carbamazepine, valproate, phenobarbital

M (72)

NA

NA

Toone et al. (1983)

Carbamazepine

M (06)

NA

NA

NA

NA

Induces changes in circulating androgen concentrations

Connell et al. (1984)

Phenytoin

M (20)

NA

NA

NA

NA

NA

NA

Reductions in free testosterone serum levels are associated with TLE in men

Herzog et al. (1986a)

Carbamazepine

F (23)

NA

NA

1 year prospective data

Isojärvi (1990)

Carbamazepine

M (21)

NA

NA

NA

1 year prospective study

Isojärvi et al. (1991)

Carbamazepine

F (32)

NA

NA

NA

NA

Low estradiol/SHBG ratios associated with menstrual disorders

Isojarvi et al. (1995)

Carbamazepine, phenytoin, phenobarbital

M (37)

NA

NA

NA

Decreased T/E2 ratio associated with hyposexuality

Murialdo et al. (1995)

carbamazepine

M (25)

NA

NA

NA

NA

NA

High SHBG levels associated with diminished potency

Isojärvi et al. (1995)

Valproate, carbamazepine

F (65)

NA

NA

NA

NA

T concentration is more elevated in women initiating treatment at the age <20 years

Isojärvi et al. (1996)

Carbamazepine

F (23)

NA

NA

NA

Murialdo et al. (1998)

Valproate

F (41)

NA

NA

NA

NA

Pre-pubertal, pubertal and Post-pubertal girls aged 8–18 year

Vainionpää et al. (1999)

Valproate

F (10)

NA

NA

NA

3 month prospective study

Rättyä et al. (2001)

Carbamazepine, lamotrigine, valproate, oxcarbazepine

M (70)

NA

NA

NA

NA

AEDs induce changes in circulating androgen concentrations

Mikkonen et al. (2004)

Carbamazepine

F (25)

NA

NA

Low E2/SHBG ratio is not associated with menstrual disorders

Löfgren et al. (2006)

Valproate, leviteracetam

M/F (20)

NA

NA

NA

Rauchenzauner et al. (2010)

Topiramate

M (36)

NA

NA

NA

NA

Hormonal changes are associated with sexual dysfunction

Urso et al. (2014)

Primidone

M/F (20)

NA

NA

NA

NA

NA

Leads to infertility in epilepsy patients

Luef and Madersbacher (2015)

Lacosamide

M (10)

NA

NA

NA

NA

NA

Cause deinduction of CYP enzymes

Elger et al. (2016)

AEDs anti-epileptic drugs, M male, F female, T testosterone, DHEAS dehydroepiandrosterone, DiT dihydrotestosterone, FT free testosterone, FAI free androgen index (100 × T/SHBG), E2 estradiol, A androstenedione, TLE temporal lobe epilepsy, NA not available

, unchanged; ↑, increased; ↓, decreased

Treatment of sexual dysfunction

Appropriate treatment to be provided for epileptic patients with sexual dysfunction requires evaluation according to patient requirements, epileptic condition and comorbidities and the medicines available for managing epilepsy. Various approaches might be helpful for treatment of sexual dysfunction in epileptic patients including;
  • Behavioral approaches to enhance sexual performance.

  • Waiting for tolerance to develop.

  • Dose reduction of current medicines.

  • Drug administration delayed until after sex.

  • Adjuvant treatment of the sexual dysfunction per se.

  • Varying the diverse range of antiepileptic’s available for individual patients.

Several adjuvant medicines i.e. buspirone, yohimbine, neostigmine, cyproheptadine, mianserin, amantadine and dexamphetamine, are used to cure AEDs related sexual dysfunction (Shapira 2003). ED in men can be treated by using indicative approaches in combination with previously described treatment approaches. This might include corporal initiation of the penis to stimulate spinal reflexes, and loss of blood can be prevented by inserting elastic constricting bands at the base, and negative pressure facilitating cavernous blood flow generated by using vacuum devices (Guldner and Morrell 1996). Additionally, methods such as the intercavernosal injection of vasodilators, i.e. papaverine or a grouping of papaverine, phentolamine, and prostaglandin E1, or yohimbine can be used to treat ED (Smaldone et al. 2004; Rokkas 2015). Other pharmaco-therapies for combatting ED to enhance the quality and frequency of erection include; topical nitroglycerine, topical minoxidil, and sildenafil (Rokkas 2015). The authors are not aware of any research that has been conducted on the use of sildenafil for ED in epileptic patients. Phosphodiesterase type-5 inhibitor drugs are now the first-line treatment for ED (Shamloul and Ghanem 2013; Bruzziches et al. 2013; Lee et al. 2015). Selective serotonin reuptake inhibitors (for example; escitalopram, paroxetine, fluoxetine, sertraline, etc.) and topical anesthetic creams are available but are not approved for the ED indication. However, they still serve as effective off-label treatments for premature ejaculation (Stimmel and Gutierrez 2006). Testosterone and aromatase inhibitors have been used in the investigational setting to treat sexual dysfunction in men taking AEDs (Hamed et al. 2013). Patient education and follow-up appointments are essential to ensure the optimal outcomes of pharmacologic treatment for sexual dysfunction in the epileptic patient. There are no approved pharmacologic treatments for female hypoactive sexual desire disorder or female orgasmic disorder. However, female sexual arousal disorder is treated with either estrogen replacement therapy or vaginal lubricants (Gutierrez et al. 2008).

Conclusions and recommendations

Sexual dysfunction in the epileptic patient is complex as it is often difficult to determine whether the dysfunction is disease or treatment related. There is a scarcity of data on the occurrence of sexual dysfunction among the population as a whole and amongst those taking AEDs which can induce sexual dysfunction. This is a broad review looking at sexual dysfunction but the primary aim is to better understand the literature surrounding sexual dysfunction in the epileptic patient where both the pathophysiology and the treatment can cause a degree of sexual dysfunction. This review concluded that the most common sexual dysfunction in males is ED and early ejaculation while females complain of lack of interest in sex and failing to reach orgasm.

Epilepsy is associated with sexual dysfunction while it is not yet known whether all AEDs have a negative impact on sexual function. Unraveling the causations of AED-induced sexual dysfunction in the epileptic patient is complicated. Sex hormone levels can be changed due to AEDs which are the cause of sexual dysfunction and reproductive disorders. Systematic studies are needed to explore the risks and mechanisms of such treatment related side effects on sexual function; particularly in epileptics. This review lead to the following recommendations for physicians in improving the management of sexual dysfunction for their patients: (1) improved electronic medical record template to include appropriate questions related to sexual dysfunction in appropriate populations such as epileptics; (2) revision of undergraduate and residency curricula to include a broader appreciation of the impact of illness processes, comorbidities, and associated pharmacotherapies upon sexual functioning; and (3) required continuing medical education on sexual dysfunction.

Abbreviations

AEDs: 

antiepileptic drugs

ED: 

erectile dysfunction

ICD-10: 

International Classification of Mental and Behavioral Disorders, 10th edition

DSM-IV: 

Diagnostic and Statistical Manual of Mental Disorders, fourth edition

DHEAS: 

dehydroepiandrosterone

DiT: 

dihydrotestosterone

FT: 

free testosterone

FAI: 

free androgen index

E2: 

estradiol

A: 

androstenedione

TLE: 

temporal lobe epilepsy

PE: 

partial epilepsy

IGE: 

idiopathic generalized epilepsy

Declarations

Authors’ contributions

MAT, MRS and SS contributed in the concept and design of this review article. MRS did the literature search. MAT and SS critically revised the paper for important intellectual content. All authors read and approved the final manuscript.

Acknowledgements

None.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

Authors’ Affiliations

(1)
Department of Pharmacy, The Islamia University of Bahawalpur
(2)
School of Management, Massey University

References

  1. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, text revision (DSM-IV-TR). American Psychiatric Association, Washington, DCView ArticleGoogle Scholar
  2. Atif M, Azeem M, Sarwar MR (2016) Potential problems and recommendations regarding substitution of generic antiepileptic drugs: a systematic review of literature. SpringerPlus 5(1):1View ArticleGoogle Scholar
  3. Baird AD, Wilson SJ, Bladin PF, Saling MM, Reutens DC (2003) Sexual outcome after epilepsy surgery. Epilepsy Behav 4(3):268–278View ArticleGoogle Scholar
  4. Baldwin DS (2001) Depression and sexual dysfunction. Br Med Bull 57(1):81–99View ArticleGoogle Scholar
  5. Baldwin D, Birtwistle J (1997) Schizophrenia, antipsychotic drugs and sexual function. Primary Care Psychiatry 3:115–124Google Scholar
  6. Baldwin DS, Thomas SC, Birtwistle J (1997) Effects of antidepressant drugs on sexual function. Int J Psychiatry Clin Pract 1(1):47–58View ArticleGoogle Scholar
  7. Bancroft J (2009) Human sexuality and its problems. Elsevier Health Sciences, AmsterdamGoogle Scholar
  8. Bauer J (2001) Interactions between hormones and epilepsy in female patients. Epilepsia 42(s3):20–22View ArticleGoogle Scholar
  9. Bauer J, Cooper-Mahkorn D (2008) Reproductive dysfunction in women with epilepsy: menstrual cycle abnormalities, fertility, and polycystic ovary syndrome. Int Rev Neurobiol 83:135–155View ArticleGoogle Scholar
  10. Bauer J, Isojärvi JI, Herzog A, Reuber M, Polson D, Taubøll E, Genton P, Van Der Ven H, Roesing B, Luef G (2002) Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management. J Neurol Neurosurg Psychiatry 73(2):121–125View ArticleGoogle Scholar
  11. Bhavsar V, Bhugra D (2013) Cultural factors and sexual dysfunction in clinical practice. Adv Psychiatr Treat 19(2):144–152View ArticleGoogle Scholar
  12. Bhugra D, de Silva P (2007) Sexual dysfunction across cultures. In: Textbook of cultural psychiatry. pp 364–378Google Scholar
  13. Bilo L, Meo R, Nappi C, Annunziato L, Striano S, Colao AM, Merola B, Buscaino GA (1988) Reproductive endocrine disorders in women with primary generalized epilepsy. Epilepsia 29(5):612–619View ArticleGoogle Scholar
  14. Bilo L, Meo R, Valentino R, Di Carlo C, Striano S, Nappi C (2001) Characterization of reproductive endocrine disorders in women with epilepsy. J Clin Endocrinol Metab 86(7):2950–2956View ArticleGoogle Scholar
  15. Blumer D, Walker AE (1967) Sexual behavior in temporal lobe epilepsy: a study of the effects of temporal lobectomy on sexual behavior. Arch Neurol 16(1):37–43View ArticleGoogle Scholar
  16. Bruzziches R, Francomano D, Gareri P, Lenzi A, Aversa A (2013) An update on pharmacological treatment of erectile dysfunction with phosphodiesterase type 5 inhibitors. Expert Opin Pharmacother 14(10):1333–1344View ArticleGoogle Scholar
  17. Burri A, Spector T (2011) Recent and lifelong sexual dysfunction in a female UK population sample: prevalence and risk factors. J Sex Med 8(9):2420–2430View ArticleGoogle Scholar
  18. Calabro R (2016) Sexual dysfunction: case report. Reactions 1583:669Google Scholar
  19. Calabrò RS, Italiano D, Militi D, Bramanti P (2012) Levetiracetam-associated loss of libido and anhedonia. Epilepsy Behav 24(2):283–284View ArticleGoogle Scholar
  20. Calabrò RS, De Luca R, Pollicino P, Bramanti P (2013) Anorgasmia during pregabalin add-on therapy for partial seizures. Epileptic Disord 15(3):358–361Google Scholar
  21. Christensen BS, Grønbæk M, Osler M, Pedersen BV, Graugaard C, Frisch M (2011) Sexual dysfunctions and difficulties in Denmark: prevalence and associated sociodemographic factors. Arch Sex Behav 40(1):121–132View ArticleGoogle Scholar
  22. Connell J, Rapeport W, Beastall G, Brodie M (1984) Changes in circulating androgens during short term carbamazepine therapy. Br J Clin Pharmacol 17(3):347–351View ArticleGoogle Scholar
  23. Crenshaw TL, Goldberg JP (1996) Sexual pharmacology: Drugs that affect sexual functioning. WW Norton & Co, New YorkGoogle Scholar
  24. Dalal A, Zhou L (2008) Gabapentin and sexual dysfunction: report of two cases. Neurologist 14(1):50–51View ArticleGoogle Scholar
  25. Dana-Haeri J, Oxley J, Richens A (1982) Reduction of free testosterone by antiepileptic drugs. BMJ 284(6309):85–86View ArticleGoogle Scholar
  26. Demerdash A, Shaalan M, Midani A, Kamel F, Bahri M (1991) Sexual behavior of a sample of females with epilepsy. Epilepsia 32(1):82–85View ArticleGoogle Scholar
  27. Edwards HE, Burnham WM, Ng MM, Asa S, MacLusky NJ (1999) Limbic seizures alter reproductive function in the female rat. Epilepsia 40(10):1370–1377View ArticleGoogle Scholar
  28. Elger CE, Rademacher M, Brandt C, Elmoufti S, Dedeken P, Eckhardt K, Tennigkeit F, De Backer M (2016) Changes in hormone and lipid levels in male patients with focal seizures when switched from carbamazepine to lacosamide as adjunctive treatment to levetiracetam: a small phase IIIb, prospective, multicenter, open-label trial. Epilepsy Behav 62:1–5View ArticleGoogle Scholar
  29. Elia J, Imbrogno N, Delfino M, Mazzilli F (2010) Retrograde ejaculation and abnormal hormonal profile in a subject under treatment with valproate and phenytoin. Arch Ital Urol Androl 82(4):193–194Google Scholar
  30. England MJ, Liverman CT, Schultz AM, Strawbridge LM (2012) Epilepsy across the spectrum: promoting health and understanding: a summary of the Institute of Medicine report. Epilepsy Behav 25(2):266–276View ArticleGoogle Scholar
  31. Ernst C, Földényi M, Angst J (1993) The Zurich Study: XXI. Sexual dysfunctions and disturbances in young adults. Eur Arch Psychiatry Clin Neurosci 243(3–4):179–188View ArticleGoogle Scholar
  32. Fogari R, Zoppi A, Corradi L, Mugellini A, Poletti L, Lusardi P (1998) Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens 11(10):1244–1247View ArticleGoogle Scholar
  33. Garde K, Lunde I (1980) Social background and social status; influence on female sexual behaviour. A random sample study of 40-year-old Danish women. Maturitas 2(3):241–246View ArticleGoogle Scholar
  34. Genton P, Bauer J, Duncan S, Taylor AE, Balen AH, Eberle A, Pedersen B, Salas-Puig X, Sauer MV (2001) On the association between valproate and polycystic ovary syndrome. Epilepsia 42(3):295–304View ArticleGoogle Scholar
  35. Gil-Nagel A, Lopez-Munoz F, Serratosa J, Moncada I, Garcia-Garcia P, Alamo C (2006) Effect of lamotrigine on sexual function in patients with epilepsy. Seizure 15(3):142–149View ArticleGoogle Scholar
  36. Gitlin M (2003) Sexual dysfunction with psychotropic drugs. Expert Opin Pharmacother 4(12):2259–2269View ArticleGoogle Scholar
  37. Goldstein BJ, Goodnick PJ (1998) Selective serotonin reuptake inhibitors in the treatment of affective disorders—III. Tolerability, safety and pharmacoeconomics. J Psychopharmacol 12(4 suppl):S55–S87Google Scholar
  38. Gorkemli H, Genc BO, Dogan EA, Genc E, Ozdemir S (2008) Long-term effects of valproic acid on reproductive endocrine functions in Turkish women with epilepsy. Gynecol Obstet Invest 67(4):223–227View ArticleGoogle Scholar
  39. Grant AC, Oh H (2002) Gabapentin-induced anorgasmia in women. Am J Psychiatry 159(7):1247View ArticleGoogle Scholar
  40. Guldner GT, Morrell MJ (1996) Nocturnal penile tumescence and rigidity evaluation in men with epilepsy. Epilepsia 37(12):1211–1214View ArticleGoogle Scholar
  41. Gutierrez MA, Mushtaq R, Stimmel G (2008) Sexual dysfunction in women with epilepsy: role of antiepileptic drugs and psychotropic medications. Int Rev Neurobiol 83:157–167View ArticleGoogle Scholar
  42. Hamed S, Mohamed K, El-Taher A, Hamed E, Omar H (2006) The sexual and reproductive health in men with generalized epilepsy: a multidisciplinary evaluation. Int J Impot Res 18(3):287–295View ArticleGoogle Scholar
  43. Hamed SA, Ahmad HK, Youssef AH, Metwaly NA-H, Hassan MM, Mohamad HO (2013) Erectile function in men with epilepsy: relationship to psychosocial, hormonal, epilepsy and antiepileptic drugsrelated variables. J Neurol Neurosci 4(2):5Google Scholar
  44. Hamed SA, Hermann BP, Moussa EM, Youssef AH, Rageh TA, Elserogy YE, NasrEldin E (2015) Evaluation of penile vascular status in men with epilepsy with erectile dysfunction. Seizure 25:40–48View ArticleGoogle Scholar
  45. Harden CL (2005) Sexuality in women with epilepsy. Epilepsy Behav 7:2–6View ArticleGoogle Scholar
  46. Harden CL (2008) Sexual dysfunction in women with epilepsy. Seizure 17(2):131–135View ArticleGoogle Scholar
  47. Hendrickx L, Gijs L, Enzlin P (2016) Sexual difficulties and associated sexual distress in Flanders (Belgium): a representative population-based survey study. The journal of sexual medicine 13(4):650–668View ArticleGoogle Scholar
  48. Herzog AG, Seibel MM, Schomer D, Vaitukaitis J, Geschwind N (1984) Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovarian syndrome? Neurology 34(10):1389View ArticleGoogle Scholar
  49. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N (1986a) Reproductive endocrine disorders in men with partial seizures of temporal lobe origin. Arch Neurol 43(4):347–350View ArticleGoogle Scholar
  50. Herzog AG, Seibel MM, Schomer DL, Vaitukaitis JL, Geschwind N (1986b) Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol 43(4):341–346View ArticleGoogle Scholar
  51. Herzog AG, Coleman AE, Jacobs AR, Klein P, Friedman MN, Drislane FW, Ransil BJ, Schomer DL (2003a) Interictal EEG discharges, reproductive hormones, and menstrual disorders in epilepsy. Ann Neurol 54(5):625–637View ArticleGoogle Scholar
  52. Herzog AG, Coleman AE, Jacobs AR, Klein P, Friedman MN, Drislane FW, Schomer DL (2003b) Relationship of sexual dysfunction to epilepsy laterality and reproductive hormone levels in women. Epilepsy Behav 4(4):407–413View ArticleGoogle Scholar
  53. Herzog A, Drislane F, Schomer D, Pennell P, Bromfield E, Dworetzky B, Farina E, Frye C (2005) Differential effects of antiepileptic drugs on sexual function and hormones in men with epilepsy. Neurology 65(7):1016–1020View ArticleGoogle Scholar
  54. Hierons R, Saunders M (1966) Impotence in patients with temporal-lobe lesions. Lancet 288(7467):761–764View ArticleGoogle Scholar
  55. Hitiris N, Barrett JA, Brodie MJ (2006) Erectile dysfunction associated with pregabalin add-on treatment in patients with partial seizures: five case reports. Epilepsy Behav 8(2):418–421View ArticleGoogle Scholar
  56. Holtkamp M, Weissinger F, Meierkord H (2005) Erectile dysfunction with topiramate. Epilepsia 46(1):166–167View ArticleGoogle Scholar
  57. Hopkinson ZE, Sattar N, Fleming R, Greer IA (1998) Fortnightly review: polycystic ovarian syndrome: the metabolic syndrome comes to gynaecology. Br Med J 317(7154):329View ArticleGoogle Scholar
  58. Isojärvi JI (1990) Serum steroid hormones and pituitary function in female epileptic patients during carbamazepine therapy. Epilepsia 31(4):438–445View ArticleGoogle Scholar
  59. Isojarvi JI, Repo M, Pakarinen AJ, Lukkarinen O, Myllylä VV (1995) Carbamazepine, phenytoin, sex hormones, and sexual function in men with epilepsy. Epilepsia 36(4):366–370View ArticleGoogle Scholar
  60. Isojärvi JI, Pakarinen AJ, Myllylä VV (1991) A prospective study of serum sex hormones during carbamazepine therapy. Epilepsy Res 9(2):139–144View ArticleGoogle Scholar
  61. Isojärvi JI, Laatikainen TJ, Pakarinen AJ, Juntunen KT, Myllylä VV (1995) Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia 36(7):676–681View ArticleGoogle Scholar
  62. Isojärvi JI, Laatikainen TJ, Knip M, Pakarinen AJ, Juntunen KT, Myllyla VV (1996) Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol 39(5):579–584View ArticleGoogle Scholar
  63. Isojärvi J, Löfgren E, Juntunen K, Pakarinen A, Päivänsalo M, Rautakorpi I, Tuomivaara L (2004) Effect of epilepsy and antiepileptic drugs on male reproductive health. Neurology 62(2):247–253View ArticleGoogle Scholar
  64. Jensen SB (1992) Sexuality and chronic illness: a biopsychosocial approach. Semin Neurol 12(2):135–140Google Scholar
  65. Kaufman K, Struck P (2011a) Dose-dependent gabapentin-induced sexual dysfunction. Epilepsia 52:228Google Scholar
  66. Kaufman KR, Struck PJ (2011b) Gabapentin-induced sexual dysfunction. Epilepsy Behav 21(3):324–326View ArticleGoogle Scholar
  67. Kaufman KR, Wong S, Sivaraaman K, Anim C, Delatte D (2015) Epilepsy and AED-induced decreased libido—the unasked psychosocial comorbidity. Epilepsy Behav 52:236–238View ArticleGoogle Scholar
  68. Keller J, Chen YK, Lin HC (2012) Association between epilepsy and erectile dysfunction: evidence from a population-based study. J Sex Med 9(9):2248–2255View ArticleGoogle Scholar
  69. Kirmani BF, Robinson DM, Kikam A, Fonkem E, Cruz D (2014) Selection of antiepileptic drugs in older people. Curr Treat Options eurol 16(6):1–16Google Scholar
  70. Lambert MV (2001) Seizures, hormones and sexuality. Seizure 10(5):319–340View ArticleGoogle Scholar
  71. Laumann EO, Paik A, Rosen RC (1999) Sexual dysfunction in the United States: prevalence and predictors. JAMA 281(6):537–544View ArticleGoogle Scholar
  72. Lee D, Nazroo J, Pendleton N (2015) Erectile dysfunction and phosphodiesterase type 5 inhibitor use: associations with sexual activities, function and satisfaction in a population sample of older men. Int J Impot Res 27(4):146–151View ArticleGoogle Scholar
  73. Lindau ST, Schumm LP, Laumann EO, Levinson W, O’Muircheartaigh CA, Waite LJ (2007) A study of sexuality and health among older adults in the United States. N Engl J Med 357(8):762–774View ArticleGoogle Scholar
  74. Löfgren E, Tapanainen JS, Koivunen R, Pakarinen A, Isojärvi JI (2006) Effects of carbamazepine and oxcarbazepine on the reproductive endocrine function in women with epilepsy. Epilepsia 47(9):1441–1446View ArticleGoogle Scholar
  75. Löfgren E, Mikkonen K, Tolonen U, Pakarinen A, Koivunen R, Myllyla VV, Tapanainen JS, Isojärvi JI (2007) Reproductive endocrine function in women with epilepsy: the role of epilepsy type and medication. Epilepsy Behav 10(1):77–83View ArticleGoogle Scholar
  76. Lombardi G, Musco S, Kessler TM, Li Marzi V, Lanciotti M, Del Popolo G (2015) Management of sexual dysfunction due to central nervous system disorders: a systematic review. BJU Int 115:47–56View ArticleGoogle Scholar
  77. Luef G, Madersbacher H (2015) Sexual dysfunction in patients with epilepsy. Handb Clin Neurol 130:383–394View ArticleGoogle Scholar
  78. Luef G, Abraham I, Haslinger M, Trinka E, Seppi K, Unterberger I, Alge A, Windisch J, Lechleitner M, Bauer G (2002a) Polycystic ovaries, obesity and insulin resistance in women with epilepsy. J Neurol 249(7):835–841View ArticleGoogle Scholar
  79. Luef G, Abraham I, Trinka E, Alge A, Windisch J, Daxenbichler G, Unterberger I, Seppi K, Lechleitner M, Krämer G (2002b) Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res 48(1):91–102View ArticleGoogle Scholar
  80. Maschio M, Saveriano F, Dinapoli L, Jandolo B (2011) Reversible erectile dysfunction in a patient with brain tumor-related epilepsy in therapy with zonisamide in add-on. J Sex Med 8(12):3515–3517View ArticleGoogle Scholar
  81. Mattson RH, Cramer JA, Collins JF, Smith DB, Delgado-Escueta AV, Browne TR, Williamson PD, Treiman DM, McNamara JO, McCutchen CB (1985) Comparison of carbamazepine, phenobarbital, phenytoin, and primidone in partial and secondarily generalized tonic–clonic seizures. N Engl J Med 313(3):145–151View ArticleGoogle Scholar
  82. McCabe MP, Sharlip ID, Lewis R, Atalla E, Balon R, Fisher AD, Laumann E, Lee SW, Segraves RT (2016) Incidence and prevalence of sexual dysfunction in women and men: a consensus statement from the Fourth International Consultation on Sexual Medicine 2015. J Sex Med 13(2):144–152View ArticleGoogle Scholar
  83. Meryn S (2015) Erectile dysfunction in the elderly. Springer, Berlin, pp 159–166Google Scholar
  84. Mialon A, Berchtold A, Michaud P-A, Gmel G, Suris J-C (2012) Sexual dysfunctions among young men: prevalence and associated factors. J Adolesc Health 51(1):25–31View ArticleGoogle Scholar
  85. Mikkonen K, Tapanainen P, Pakarinen AJ, Päivänsalo M, Isojärvi JI, Vainionpää LK (2004) Serum androgen levels and testicular structure during pubertal maturation in male subjects with epilepsy. Epilepsia 45(7):769–776View ArticleGoogle Scholar
  86. Montejo-Gonzalez AL, Llorca G, Izquierdo J, Ledesma A, Bousono M, Calcedo A, Carrasco J, Ciudad J, Daniel E, De La Gandara J (1997) Fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Ther 23(3):176–194View ArticleGoogle Scholar
  87. Morrell MJ (2003) Reproductive and metabolic disorders in women with epilepsy. Epilepsia 44(s4):11–20View ArticleGoogle Scholar
  88. Morrell MJ, Guldner GT (1996) Self-reported sexual function and sexual arousability in women with epilepsy. Epilepsia 37(12):1204–1210View ArticleGoogle Scholar
  89. Morrell MJ, Flynn KL, Doñe S, Flaster E, Kalayjian L, Pack AM (2005) Sexual dysfunction, sex steroid hormone abnormalities, and depression in women with epilepsy treated with antiepileptic drugs. Epilepsy Behav 6(3):360–365View ArticleGoogle Scholar
  90. Murialdo G, Galimberti CA, Fonzi S, Manni R, Costelli P, Parodi C, Solinas GP, Amoretti G, Tartara A (1995) Sex hormones and pituitary function in male epileptic patients with altered or normal sexuality. Epilepsia 36(4):360–365View ArticleGoogle Scholar
  91. Murialdo G, Galimberti C, Magri F, Sampaolo P, Copello F, Gianelli M, Gazzerro E, Rollero A, Deagatone C, Manni R (1997) Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest 20(9):519–526View ArticleGoogle Scholar
  92. Murialdo G, Galimberti C, Gianelli M, Rollero A, Polleri A, Copello F, Magri F, Ferrari E, Sampaolo P, Manni R (1998) Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol 21(1):52–58Google Scholar
  93. Nathan SG (1986) The epidemiology of the DSM-III psychosexual dysfunctions. J Sex Marital Ther 12(4):267–281View ArticleGoogle Scholar
  94. Nikoobakht M, Motamedi M, Orandi A, Meysamie A, Emamzadeh A (2007) Sexual dysfunction in epileptic men. Urol J 4(2):111–117Google Scholar
  95. Osborn M, Hawton K, Gath D (1988) Sexual dysfunction among middle aged women in the community. BMJ 296(6627):959–962View ArticleGoogle Scholar
  96. Perloff MD, Thaler DE, Otis JA (2011) Anorgasmia with gabapentin may be common in older patients. Am J Geriatr Pharmacother 9(3):199–203View ArticleGoogle Scholar
  97. Quigg M, Kiely JM, Shneker B, Veldhuis JD, Bertram EH (2002) Interictal and postictal alterations of pulsatile secretions of luteinizing hormone in temporal lobe epilepsy in men. Ann Neurol 51(5):559–566View ArticleGoogle Scholar
  98. Rättyä J, Pakarinen AJ, Knip M, Repo-Outakoski M, Myllylä VV, Isojärvi JI (2001) Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology 57(3):440–444View ArticleGoogle Scholar
  99. Rauchenzauner M, Bitsche G, Svalheim S, Tauboll E, Haberlandt E, Wildt L, Rostasy K, Luef G (2010) Effects of levetiracetam and valproic acid monotherapy on sex-steroid hormones in prepubertal children—results from a pilot study. Epilepsy Res 88(2):264–268View ArticleGoogle Scholar
  100. Rauchenzauner M, Roscia S, Prieschl M, Wildt L, Haberlandt E, Baumann M, Rostasy K, Agostinelli S, Pizzolorusso A, Luef G (2014) Reproductive endocrine health in pubertal females with epilepsy on antiepileptic drugs: time to screen? Neuropediatrics 45(04):226–233View ArticleGoogle Scholar
  101. Rokkas K (2015) Management of erectile dysfunction beyond PDE-5 inhibitors. Springer, Berlin, pp 195–203Google Scholar
  102. Safarinejad M (2006) Female sexual dysfunction in a population-based study in Iran: prevalence and associated risk factors. Int J Impot Res 18(4):382–395View ArticleGoogle Scholar
  103. Scharfman HE, Kim M, Hintz TM, MacLusky NJ (2008) Seizures and reproductive function: insights from female rats with epilepsy. Ann Neurol 64(6):687–697View ArticleGoogle Scholar
  104. Shamloul R, Ghanem H (2013) Erectile dysfunction. Lancet 381(9861):153–165View ArticleGoogle Scholar
  105. Shapira N (2003) Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction. Google PatentsGoogle Scholar
  106. Sivaraaman K, Mintzer S (2011) Hormonal consequences of epilepsy and its treatment in men. Curr Opin Endocrinol Diabetes Obes 18(3):204–209View ArticleGoogle Scholar
  107. Smaldone M, Sukkarieh T, Reda A, Khan A (2004) Epilepsy and erectile dysfunction: a review. Seizure 13(7):453–459View ArticleGoogle Scholar
  108. Stimmel GL, Gutierrez MA (2006) Pharmacologic treatment strategies for sexual dysfunction in patients with epilepsy and depression. CNS Spectr 11(S9):31–37View ArticleGoogle Scholar
  109. Sungur MZ, Bez Y (2016) cultural factors in the treatment of sexual dysfunction in Muslim clients. Curr Sex Health Rep 8(2):57–63View ArticleGoogle Scholar
  110. Svalheim S, Sveberg L, Mochol M, Taubøll E (2015) Interactions between antiepileptic drugs and hormones. Seizure 28:12–17View ArticleGoogle Scholar
  111. Tassone DM, Boyce E, Guyer J, Nuzum D (2007) Pregabalin: a novel γ-aminobutyric acid analogue in the treatment of neuropathic pain, partial-onset seizures, and anxiety disorders. Clin Ther 29(1):26–48View ArticleGoogle Scholar
  112. Toone B, Wheeler M, Nanjee M, Fenwick P, Grant R (1983) Sex hormones, sexual activity and plasma anticonvulsant levels in male epileptics. J Neurol Neurosurg Psychiatry 46(9):824–826View ArticleGoogle Scholar
  113. Urso L, Zummo L, Gammino M, Fierro B, Pavone C, Daniele O (2014) Antiepileptic drugs, sexual functions and serum hormonal profile in males with epilepsy. Med Surg Urol 3:130. doi:10.4172/2168-9857.1000130
  114. Vainionpää LK, Rättyä J, Knip M, Tapanainen JS, Pakarinen AJ, Lanning P, Tekay A, Myllylä VV, Isojärvi JI (1999) Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol 45(4):444–450View ArticleGoogle Scholar
  115. Verrotti A, D’Egidio C, Mohn A, Coppola G, Parisi P, Chiarelli F (2011) Antiepileptic drugs, sex hormones, and PCOS. Epilepsia 52(2):199–211Google Scholar
  116. Verrotti A, Prezioso G, D’Egidio C, Belcastro V (2015) Reproductive hormones in epilepsy therapy: from old promises to new hopes. In: Epilepsy towards the next decade. Springer, Berlin, pp 201–211Google Scholar
  117. World Health Organization (1992) The ICD-10 classification of mental and behavioural disorders: clinical descriptions and diagnostic guidelines. World Health Organization, GenevaGoogle Scholar
  118. Xiaotian X, Hengzhong Z, Yao X, Zhipan Z, Daoliang X, Yumei W (2013) Effects of antiepileptic drugs on reproductive endocrine function, sexual function and sperm parameters in Chinese Han men with epilepsy. J Clin Neurosci 20(11):1492–1497View ArticleGoogle Scholar

Copyright

© The Author(s) 2016